SCHEMBL351719

SCHEMBL351719

c1ccc(CN2CCCOCC2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.64
SIGMAR1 Q99720 4/20 0.61
ALDH1A1 P00352 3/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
HTT P42858 2/20 0.58
KDM4E B2RXH2 1/20 0.58
HPGD P15428 1/20 0.58
LTA4H P09960 1/20 0.57
NCF1 P14598 1/20 0.56
TSHR P16473 2/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
DRD4 P21917 1/20 0.55
CYP2A13 Q16696 1/20 0.54
POLB P06746 1/20 0.54
TP53 P04637 1/20 0.53
MAPK1 P28482 1/20 0.53
HIF1A Q16665 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24200050 0.98 HRH3 (0.62) HRH3SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL6102208 0.93 HRH3 (0.57) HRH3SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL102338 0.92 SIGMAR1 (0.71) HRH3SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL6200777 0.92 SIGMAR1 (0.71) HRH3SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL948372 0.90 SIGMAR1 (0.68) HRH3SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL18065638 0.90 SIGMAR1 (0.68) HRH3SIGMAR1ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL6261135 0.90 SIGMAR1 (0.68) HRH3SIGMAR1ALDH1A1MEN1KMT2A
Water SCHEMBL1702298 0.90 SIGMAR1 (0.68) HRH3SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL896379 0.90 SIGMAR1 (0.68) HRH3SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL28158277 0.90 SIGMAR1 (0.68) HRH3SIGMAR1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731223-A1 MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY Universitat De Barcelona (ES) 2026-04-29 EP claimed
WO-2024261340-A1 MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY UNIVERSITAT DE BARCELONA (ES) 2024-12-26 WO claimed
EP-4731223-A1 MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY Universitat De Barcelona (ES) 2026-04-29 EP disclosed
WO-2024261340-A1 MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY UNIVERSITAT DE BARCELONA (ES) 2024-12-26 WO disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 EP disclosed
WO-2023193054-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2023-10-12 WO disclosed
US-20230278969-A1 CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS BIOPHARMA CREDIT PLC (GB) 2023-09-07 US disclosed
WO-2023134656-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF 上海壹典医药科技开发有限公司 2023-07-20 WO disclosed
WO-2021132577-A1 ACYLSULFAMIDE COMPOUND AND PHARMACEUTICAL USE THEREFOR 日本たばこ産業株式会社 2021-07-01 WO disclosed
EP-3323814-B1 (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS ASTRAZENECA AB (SE) 2020-05-13 EP disclosed
WO-2019215341-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 WO disclosed
EP-3323814-A1 (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS AstraZeneca AB (SE) 2018-05-23 EP disclosed
US-8648190-B2 Process for producing 2-hydroxymethylmorpholine salt DAISO CO., LTD. (JP) 2014-02-11 US disclosed
EP-2388252-B1 PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT DAISO CO LTD (JP) 2013-07-24 EP disclosed
US-20120016120-A1 PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT DAISO CO., LTD. (JP) 2012-01-19 US disclosed
EP-2388252-A1 PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT Daiso Co., Ltd. (JP) 2011-11-23 EP disclosed
US-8040010-B2 Permanent magnet type generator and hybrid vehicle using the same HITACHI, LTD. (JP) 2011-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016120-A1 PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT THOP1, AVPR2, HPD HRH3 74/4885SIGMAR1 740/4885ALDH1A1 1900/4885
US-20230278969-A1 CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS DPP4, DPP7, DPEP1 HRH3 1926/4885SIGMAR1 2219/4885ALDH1A1 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.